Injection of Glatiramer Acetate Depot Results in T1 and T2 Lesion Reduction in Relapsing MS.

Published Date: 01 Mar 2023

Secondary results from a phase 3 study show that patients with multiple sclerosis receiving glatiramer acetate depot therapy have significantly fewer new T1 enhancing lesions and new, enlarging hyperintense T2 lesions.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Additional imaging techniques can detect early stage cancers missed by mammograms in women with dense breasts

2.

Omicron Infections Are Usually Cleared Up in Immunocompromised Patients.

3.

EBV Screening Tied to Lower Nasopharyngeal Cancer Mortality Risk

4.

FDA Approves Hemophilia B Second Gene Therapy.

5.

What Kate Middleton Reminds Us About the Role of Privacy in Healing.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot